



WOMAN-2 END OF YEAR BULLETIN



CONGRATULATIONS TO ALL
FOR THE MOST SUCCESSFUL
YEAR OF THE WOMAN-2 TRIAL

2022 has been an incredible year for the trial, with over 4,400 women recruited. Following this, we are well on track to reach our target of randomising 15,000 women in 2023

Thanks to all who joined the Global Principal Investigator Meetings held at the beginning of the month, we are thrilled to show such a clear relationship between anaemia and the risk of PPH. This is all thanks to the high-quality data collected by yourselves

“ *The data collected by the WOMAN-2 Collaborators has already produced impactful evidence of the relationship between maternal anaemia and the risk of PPH* ”

THANK YOU FOR BEING PART OF
THIS JOURNEY WITH US.
WE LOOK FORWARD TO ACHIEVING
OUR TARGET AND COMPLETING THE
WOMAN-2 TRIAL IN THE NEW YEAR

NIGERIA - 403



This year had been one of intense activities. Unlike other years, we had no disruptions due to industrial actions which helped stabilize recruitment. Improvement in ante-natal care given to patients inspired by the trial is a welcome development but may have reduced the eligibility of patients. We also experienced a high turnover of Research Assistants, which called for more training sessions and increased engagement with the sites.

We look forward to a better year in 2023 with more efficient trial coordination as we apply lessons learnt this year, especially as we welcome additional sites into the study in the new year.

PAKISTAN - 3,208



Yet another fruitful year for the WOMAN-2 trial, together crossed the 11,000 milestone in 2022. We are incredibly proud of our sites' teams for this achievement and appreciative of their outstanding performance. We feel extremely lucky to have the best network of collaborators in the world. Congratulation everyone for your amazing contribution.

With another 4,000 participants to be enrolled, we are hopeful that with the enormous assistance of site teams, this can be achievable. One of the paramount achievements for Pakistan specifically, is that the trial serves as an incubator and nurtures a new generation of researchers who in the future will play an active role in transforming the research landscape of the country. Many thanks for working with us.



WOMAN-2 END OF YEAR NEWSLETTER

DECEMBER 2022

A MESSAGE FROM THE CLINICAL TRIALS UNIT

Dear wonderful collaborators,
Firstly, thank you all for a fantastic year for the WOMAN-2 trial - it has truly been inspirational.

We would like to acknowledge that the workload has been especially high this year. Primary outcome monitoring is a huge task on top of all clinical duties, however it gives confidence in the outcome of the trial.

Additionally, we would like to praise you for your amazing follow-up rate of 99.7%, this is amazing and reflects your enthusiasm for the trial when explaining outcome procedures to the women.

We appreciate every minute of your time given to the WOMAN-2 trial.

Here is to a successful 2023!



FAST FACTS

01

OCTOBER WAS THE HIGHEST RECRUITING MONTH OF THE TRIAL - 600 WOMEN!

While seasonality is expected at sites for various reasons, the high number of women recruited during October was likely as the sites in Pakistan were recruiting women < 10 g/dL instead of < 9 g/dL. Additionally, the high season began in Tanzania.

02

THE RELATIONSHIP BETWEEN ANAEMIA AND POST-PARTUM HAEMORRHAGE

The data you collected so far has shown the strong relationship between pre-birth haemoglobin and risk of PPH. For moderately to severely anaemic women, a 10g/L reduction in pre-delivery haemoglobin is associated with a 23% increased risk of PPH.

We hope that the results will be submitted to a journal early in the New Year on behalf of the WOMAN-2 Collaborators.

TANZANIA - 709



On behalf of the Tanzania National Coordinating Center, I wish to humbly recognize the 5 sites that have led to this remarkable progress. We wish to convey our heartfelt congratulations to all the site PIs, Research Fellows, Clinical Team members, Pharmacists and any other persons working with the sites who contributed to this success.

Last, but not least, we convey our sincere thanks to all women who agreed to participate in the WOMAN-2 Trial, without whom there would be nothing to talk about. To all, we wish a Merry Christmas and a bright, prosperous New Year, 2023.

ZAMBIA - 403



The team at Women and Newborn Hospital has been very busy this last quarter of 2022 as we work towards evidence generation to better women's lives!

We have seen an unprecedented number of randomisations in the trial owing to the great dedication and teamwork by all involved.

Continuous evaluation of our work and effective communication has helped a great deal in the growth of the research team. I'm looking forward to continued teamwork and positive contributions in 2023.

